Kamada Ltd stock (IL0010952647): Biopharma player focuses on plasma and inhaled therapies after recent share weakness

Kamada Ltd shares have come under pressure in recent weeks, while the Israeli biopharma group continues to focus on specialty plasma-derived products and inhaled therapies for rare and serious conditions. Recent quarterly figures and portfolio updates keep the stock on the radar of health care investors.

Kamada Ltd is a specialty biopharmaceutical company from Israel that focuses on plasma-derived therapies and specialty treatments for rare and serious conditions, including lung diseases and immune deficiencies. According to the company, Kamada develops, manufactures, and markets a portfolio of proprietary products, with a particular focus on alpha-1 antitrypsin (AAT) therapies and immunoglobulin products for patients in global markets, including the United States and Europe, as outlined in recent investor materials on the firm’s website Kamada investors page as of 04/2026.

In recent months, the stock has been volatile. A ranking of monthly movers in June 2026 shows Kamada with a negative performance over the period, reflecting a decline of several percentage points and a market capitalization in the lower hundreds of millions of dollars, according to a performance overview for the month of June 2026 that lists Kamada among healthcare stocks from Israel StockTitan as of 06/2026. While short-term performance has been weak, the company’s strategic focus on niche biopharmaceutical segments continues to attract attention from investors who follow the global health care and biotech sector.

As of: 10.06.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Kamada Ltd
• Sector/industry: Biopharmaceuticals / biotechnology
• Headquarters/country: Rehovot, Israel
• Core markets: United States, Europe, Israel
• Key revenue drivers: Plasma-derived therapies and specialty treatments
• Home exchange/listing venue: Nasdaq (ticker: KMDA) and Tel Aviv Stock Exchange
• Trading currency: USD on Nasdaq, ILS on TASE

Kamada Ltd: core business model

Kamada Ltd positions itself as a commercial-stage biopharmaceutical company focused on plasma-derived protein therapeutics and other specialty treatments for orphan and rare indications. According to its corporate description, the company’s business model integrates development, manufacturing, and commercialization of proprietary therapies as well as distribution of products under strategic licensing and supply agreements Kamada website as of 04/2026. This integrated approach aims to give Kamada control over key parts of the value chain, from plasma collection and processing to finished product supply.

A central pillar of Kamada’s portfolio is its alpha-1 antitrypsin (AAT) products, which are used to treat patients with AAT deficiency, a rare genetic disorder that can cause serious lung disease. The company has long experience in this field and has developed an intravenous AAT therapy that is marketed in several countries through different partners, while also pursuing inhaled formulations of AAT for certain patient segments, according to product overviews and pipeline descriptions in its investor presentations Kamada investors page as of 04/2026. These therapies are often reimbursed under specialized insurance or public health systems, given the rare disease context.

Beyond AAT, Kamada’s business model includes immunoglobulin products and other specialty plasma-derived therapies. The company operates a plasma fractionation facility and leverages its technology platform to produce a range of immunoglobulin and hyper-immune products used in the prevention and treatment of infectious diseases and immune-related conditions, as outlined in its corporate materials Kamada website as of 04/2026. By targeting a mix of chronic therapies for rare diseases and acute use products in hospital settings, Kamada aims to build a diversified revenue base across geographies.

The company also engages in contract manufacturing and strategic collaborations, where Kamada uses its manufacturing capabilities to produce plasma-derived or related biologic products on behalf of partners in various markets. According to management commentary in past investor communications, these collaborations can help improve capacity utilization at its manufacturing sites and provide additional revenue streams while reducing reliance on any single product or region Kamada investors page as of 04/2026. This model positions Kamada somewhere between a pure-play proprietary drug company and a specialty contract manufacturer.

Main revenue and product drivers for Kamada Ltd

Kamada’s revenue base is primarily driven by plasma-derived products, in particular its AAT therapies and its immunoglobulin portfolio. In recent financial reports, the company has highlighted growth in its immunoglobulin business and the contribution from both proprietary medications and distributed products under license agreements, with geographic diversification across the United States, Europe, and other territories. While the exact figures vary by quarter, the emphasis on double-digit growth in certain product categories has been a recurring theme in management’s commentary on recent results Kamada investors page as of 03/2026.

One driver of revenue is the company’s strategy to expand indications and geographies for its existing products. For AAT therapies, Kamada and its partners have been working to secure and maintain regulatory approvals in multiple jurisdictions and to penetrate patient populations that remain underdiagnosed in many countries, including in the United States and Europe. According to company statements, efforts such as physician education, improved diagnostic pathways, and broader payer coverage are part of the strategy to increase the treated patient base for AAT deficiency therapies over time Kamada website as of 03/2026.

In addition, Kamada’s revenue mix benefits from its focus on hyper-immune and immunoglobulin products that address infectious diseases and immune disorders. These treatments can be used in hospital and specialty care settings, where demand may be influenced by epidemiological trends and public health programs. During previous periods of heightened infectious disease awareness, such products have seen fluctuating demand, and Kamada has noted the importance of maintaining supply reliability and quality to support long-term customer relationships, according to its corporate communications and product updates Kamada investors page as of 02/2026.

Another important factor for the company’s revenue outlook is pricing and reimbursement conditions in its key markets. For rare disease treatments, pricing can be relatively high per patient, but reimbursement is often subject to negotiations with insurers and public health authorities. Kamada has indicated in previous reports that it seeks to balance access and affordability with the need to fund ongoing research and development, manufacturing upgrades, and plasma collection capabilities. This balancing act is typical for companies in the specialty plasma and rare disease space, where long-term patient relationships and sustained treatment adherence can be critical to revenue stability Kamada investors page as of 02/2026.

The company’s results are also influenced by foreign exchange effects, given that Kamada reports in U.S. dollars but incurs costs and generates revenue in multiple currencies, including Israeli shekels and euros. Fluctuations in exchange rates can therefore have an impact on reported revenue and profitability from period to period. Investors in the U.S. market typically monitor these currency effects alongside operational metrics such as volumes, average selling prices, and product mix when assessing the performance of international biopharmaceutical companies like Kamada, as highlighted in sector commentary from health care analysts following plasma and specialty biotech companies StockTitan as of 06/2026.

Conclusion

Kamada Ltd is a niche biopharmaceutical company with a focus on plasma-derived therapies and specialty treatments for rare and serious conditions, operating manufacturing and commercialization activities across multiple regions. The stock has shown weakness in recent weeks, reflecting broader volatility in smaller health care names, but the company continues to pursue its strategy of expanding its AAT and immunoglobulin portfolio and deepening its presence in key markets such as the United States and Europe. For U.S.-based investors, Kamada offers exposure to the global plasma and rare disease segment through its Nasdaq listing, coupled with the typical opportunities and risks associated with a specialized international biotech with a concentrated product portfolio and evolving regulatory and reimbursement landscape.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.